<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03108443</url>
  </required_header>
  <id_info>
    <org_study_id>1022071</org_study_id>
    <nct_id>NCT03108443</nct_id>
  </id_info>
  <brief_title>Novel Markers for Detecting Early Progression of Glaucoma</brief_title>
  <official_title>Novel Markers for Detecting Early Progression of Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Balwantray Chauhan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nova Scotia Health Authority</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current methods of detecting glaucoma and monitoring its progression over time involve visual&#xD;
      assessment of the optic nerve, thickness measurements of nerve tissue in the eye (using&#xD;
      optical coherence tomography, OCT) as well as functional tests which measure peripheral, or&#xD;
      side, vision. The objective of this study is to determine if a new technique of measuring&#xD;
      blood flow in the eye, using OCT, can be used to better detect and/or monitor changes in&#xD;
      glaucoma patients and suspects than these methods.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Changes in the superficial optic nerve head (ONH) surface and loss of retinal nerve fibre&#xD;
      layer (RNFL) thickness detected with clinical imaging are predictive of future visual field&#xD;
      loss. Imaging of the deep ONH, the likely origin of glaucomatous damage, represents the next&#xD;
      logical next step, but has eluded clinicians because of the lack of capable technology.&#xD;
&#xD;
      New advances in optical coherence tomography (OCT) imaging now offer an exciting opportunity&#xD;
      to close the gap between the histomorphometric knowledge on deep ONH changes gained with&#xD;
      research in experimental monkey glaucoma and imaging in clinical glaucoma.&#xD;
&#xD;
      There is compelling evidence that gross ONH and retinal hemodynamic changes are functional&#xD;
      indicators of glaucoma progression. Accurate tracking of blood flow in the ONH is a logical&#xD;
      step, but has evaded researchers for several reasons including the highly reflective ONH&#xD;
      tissue which variably inhibits signal penetration making the complex nature of retinal and&#xD;
      posterior ciliary contributions to ONH flow difficult to segregate. Even though glaucoma&#xD;
      damage originates in the ONH, retinal ganglion cell (RGC) axons may show the earliest&#xD;
      functional alterations as they have high metabolic demand and vulnerability to damage.&#xD;
      Therefore, tracking blood flow in the RNFL, which is highly segmental and resolvable, could&#xD;
      be a better and more sensitive approach compared to that in the ONH. The macula contains&#xD;
      almost 50% of the entire RGC population; likewise, monitoring blood flow in the macular inner&#xD;
      vascular plexus corresponding to the ganglion cell layer (GCL) is likely to be highly&#xD;
      informative for glaucoma progression. OCT based angiography (OCTA), which maps vessel density&#xD;
      in different retinal vascular beds with unparalleled axial resolution, will finally allow us&#xD;
      to quantify highly localized parameters related to blood flow and identify patients with&#xD;
      higher progression risk. Current data analysis of progression detection based on&#xD;
      inter-subject or population-based variability models are inefficient, leading to&#xD;
      false-positive and false-negative results. Innovative data analysis techniques that build&#xD;
      accurate models of intra-subject variability will add cumulative value to the novel imaging&#xD;
      markers for progression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Blood flow</measure>
    <time_frame>Changes over the 5 year course of the study</time_frame>
    <description>Establish whether blood flow changes occur and if there are differences in the groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Optic nerve head (ONH) anatomy</measure>
    <time_frame>Changes over the 5 year course of the study</time_frame>
    <description>Measure changes in the structure of the ONH</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Glaucoma</arm_group_label>
    <description>Subjects identified as having glaucoma. No interventions will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>Subjects identified as having healthy eyes with no disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Optical Coherence tomography angiography</intervention_name>
    <description>All subjects will have OCT angiography imaging performed</description>
    <arm_group_label>Glaucoma</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Glaucoma patients recruited from a Primary Care Clinic Healthy control subjects recruited&#xD;
        from the general population&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Glaucoma Group&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  visual acuity ≥ 6/12&#xD;
&#xD;
          -  glaucomatous ONH change&#xD;
&#xD;
          -  glaucomatous visual field loss with a positive Glaucoma Hemifield Test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  non-glaucomatous ocular disease&#xD;
&#xD;
          -  chronic systemic disease or treatment affecting the visual field&#xD;
&#xD;
          -  refraction exceeding 6 D equivalent sphere or 3 D astigmatism&#xD;
&#xD;
          -  inability to provide informed consent&#xD;
&#xD;
        Control Group&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  visual acuity ≥ 6/12&#xD;
&#xD;
          -  normal eye examination with intraocular pressure ≤ 21 mm Hg&#xD;
&#xD;
          -  normal visual field and negative Glaucoma Hemifield Test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  chronic ocular disease&#xD;
&#xD;
          -  chronic systemic disease or treatment affecting the visual field&#xD;
&#xD;
          -  refraction exceeding 6 D equivalent sphere or 3 D astigmatism&#xD;
&#xD;
          -  inability to provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Balwantray Chauhan, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nova Scotia Health Authority</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eye Care Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 5, 2017</study_first_submitted>
  <study_first_submitted_qc>April 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2017</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nova Scotia Health Authority</investigator_affiliation>
    <investigator_full_name>Balwantray Chauhan</investigator_full_name>
    <investigator_title>Mathers Professor and Research Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

